Calcium acetate - Warnings and Precautions
The following warnings and precautions are taken directly from the US FDA-approved drug label for Calcium acetate. This is the same information dispensing pharmacists read.
5 WARNINGS AND PRECAUTIONS Treat mild hypercalcemia by reducing or interrupting calcium acetate and Vitamin D.
Severe hypercalcemia may require hemodialysis and discontinuation of calcium acetate capsules.
Hypercalcemia may aggravate digitalis toxicity.
5.1 Hypercalcemia Patients with end stage renal disease may develop hypercalcemia when treated with calcium, including calcium acetate.
Avoid the use of calcium supplements, including calcium-based nonprescription antacids, concurrently with calcium acetate.
An overdose of calcium acetate may lead to progressive hypercalcemia, which may require emergency measures.
Therefore, early in the treatment phase during the dosage adjustment period, monitor serum calcium levels twice weekly.
Should hypercalcemia develop, reduce the calcium acetate dosage or discontinue the treatment, depending on the severity of hypercalcemia.
More severe hypercalcemia (Ca>12 mg/dL) is associated with confusion, delirium, stupor and coma.
Severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate therapy.
Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting.
Mild hypercalcemia is usually controlled by reducing the calcium acetate dose or temporarily discontinuing therapy.
Decreasing or discontinuing Vitamin D therapy is recommended as well.
Chronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification.
Radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification.
The long term effect of calcium acetate on the progression of vascular or soft tissue calcification has not been determined.
Hypercalcemia (>11 mg/dL) was reported in 16% of patients in a 3-month study of a solid dose formulation of calcium acetate; all cases resolved upon lowering the dose or discontinuing treatment.
Maintain the serum calcium-phosphorus (Ca x P) product below 55 mg 2 /dL 2 .
5.2 Concomitant Use with Medications Hypercalcemia may aggravate digitalis toxicity.
Applies to YOU?
Some warnings apply only to specific age groups, health conditions, or other medicines. Ask GoDavaii AI to filter which of these 19+ warnings apply to your profile.
Ask Health AI \u2192